5 Key Takeaways
-
1
Stuart Therapeutics, Inc. appointed Dave LeCause as senior commercial advisor to lead its commercial strategy.
-
2
LeCause will oversee the advancement of ST-100, the company's lead therapeutic candidate for dry eye disease.
-
3
ST-100 is anticipated to enter Phase 3b clinical trials in the first quarter of 2027.
-
4
LeCause previously held key roles at Allergan, including vice president and general manager of the eye care franchise.
-
5
Eric Schlumpf, CEO of Stuart Therapeutics, emphasized LeCause's experience in launching first-in-class therapies.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
